Voyager Therapeutics (VYGR) reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.
Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.
The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.
Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography (PET) imaging data in H2 2026.
Voyager shares were down nearly 3% in recent trading.
Price: 3.97, Change: -0.11, Percent Change: -2.70
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。